Treatment ofALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context-Reference-Cited by-同舟云学术

Treatment ofALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context

Published:2017-08 Issue: Volume:13 Page:3-13
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Itchins M.¹²³,Chia P.L.⁴⁵⁶,Hayes S.A.¹²,Howell V.M.¹²,Gill A.J.²⁷,Cooper W.A.²⁸⁹,John T.⁴⁵⁶,Mitchell P.⁴⁵⁶,Millward M.¹⁰¹¹¹²,Clarke S.J.¹²³¹³,Solomon B.¹⁴¹⁵,Pavlakis N.¹²³¹³

Affiliation:

1. Bill Walsh Translational Research Laboratory; Kolling Institute Medical Institute of Research, Royal North Shore Hospital; St Leonards New South Wales Australia

2. Sydney Medical School; Northern Clinical School; University of Sydney; Sydney New South Wales Australia

3. Northern Cancer Institute; St Leonards New South Wales Australia

4. Medical Oncology Unit; Olivia Newton John Cancer and Wellness Centre; Austin Health; Melbourne

5. Olivia Newton-John Cancer Research Institute; Melbourne Australia

6. Department of Medicine, Dentistry and Health Sciences; The University of Melbourne; Melbourne Victoria Australia

7. Cancer Diagnosis and Pathology Group; Kolling Institute of Medical Research, Royal North Shore Hospital; St Leonards New South Wales Australia

8. Department of Tissue Pathology and Diagnostic Oncology; Royal Prince Alfred Hospital; Sydney New South Wales Australia

9. School of Medicine; Western Sydney University; Sydney New South Wales Australia

10. School of Medicine; University of Western Australia; Perth Western Australia Australia

11. Department of Medical Oncology; Sir Charles Gairdner Hospital; Nedlands Western Australia Australia

12. Linear Clinical Research; Nedlands Western Australia Australia

13. Department of Medical Oncology; Royal North Shore Hospital; St Leonards New South Wales Australia

14. Department of Medical Oncology; Peter MacCallum Cancer Centre; Melbourne Victoria Australia

15. Sir Peter MacCallum Department of Oncology; University of Melbourne; Parkville Victoria Australia

Funder

Ilse Schnell Cancer Research

NSW Ministry of Health

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12754/fullpdf

Reference86 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Estimated incidence, mortality and prevalence worldwide in 2012;International Agency for Research on Cancer. World Health Organization;GLOBOCAN 2012,2012

3. Foundation ACR Lung Cancer 2017

4. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset;Inamura;Mod Pathol,2009

5. Targeting anaplastic lymphoma kinase in lung cancer;Shaw;Clin Cancer Res,2011

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer;Frontiers in Public Health;2024-02-15

2. Squamous cell carcinoma differentiation at progression as a resistance mechanism in metastatic non-small cell lung carcinoma harbouring a targetable mutation;Pathology;2022-12

3. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective;Journal of Managed Care & Specialty Pharmacy;2022-09

4. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study;Frontiers in Pharmacology;2022-03-17

5. Pharmacophore screening, molecular docking, ADMET prediction and MD simulations for identification of ALK and MEK potential dual inhibitors;Journal of Molecular Structure;2021-12